Cargando…

TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

BACKGROUND: About 20% of resectable oesophageal carcinoma is resistant to preoperative chemoradiotherapy. Here we hypothesised that the expression of the antiapoptotic gene Baculoviral inhibitor of apoptosis repeat containing (BIRC)3 induced by the transforming growth factor β activated kinase 1 (TA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piro, G, Giacopuzzi, S, Bencivenga, M, Carbone, C, Verlato, G, Frizziero, M, Zanotto, M, Mina, M M, Merz, V, Santoro, R, Zanoni, A, De Manzoni, G, Tortora, G, Melisi, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578082/ https://www.ncbi.nlm.nih.gov/pubmed/26291056 http://dx.doi.org/10.1038/bjc.2015.283

Ejemplares similares

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects
por: Li, Q, et al.
Publicado: (2011)

Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients
por: Wadhwa, Roopma, et al.
Publicado: (2017)

Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers
por: Al-Attar, A, et al.
Publicado: (2010)

Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer
por: Suzuki, S, et al.
Publicado: (2014)

Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer
por: Gibault, L, et al.
Publicado: (2005)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas
por: Slotta-Huspenina, J, et al.
Publicado: (2013)

Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma
por: Watanabe, M, et al.
Publicado: (2010)

Low stromal Foxp3(+) regulatory T-cell density is associated with complete response to neoadjuvant chemoradiotherapy in rectal cancer
por: McCoy, M J, et al.
Publicado: (2015)

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin
por: Wu, X, et al.
Publicado: (2009)

ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer
por: Watanabe, T, et al.
Publicado: (2015)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Macrophage subtype predicts lymph node metastasis in oesophageal adenocarcinoma and promotes cancer cell invasion in vitro
por: Cao, Wenqing, et al.
Publicado: (2015)

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
por: Damiano, V, et al.
Publicado: (2013)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer
por: Rosa, R, et al.
Publicado: (2013)

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours
por: Gelardi, T, et al.
Publicado: (2010)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy
por: Fareed, K R, et al.
Publicado: (2010)

Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours
por: Zucali, P A, et al.
Publicado: (2013)

Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin
por: Giovannetti, E, et al.
Publicado: (2011)

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma
por: Santoro, A, et al.
Publicado: (2010)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival
por: Robinson, C G, et al.
Publicado: (2010)

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity
por: den Brok, M H M G M, et al.
Publicado: (2006)

Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact
por: Alì, G, et al.
Publicado: (2009)

Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead
por: Mangoni, M, et al.
Publicado: (2012)

Texture analysis of (125)I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response
por: Rajkumar, V, et al.
Publicado: (2015)

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
por: Lorusso, D, et al.
Publicado: (2012)

A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours
por: Borriello, M, et al.
Publicado: (2011)

The semisynthetic flavonoid monoHER sensitises human soft tissue sarcoma cells to doxorubicin-induced apoptosis via inhibition of nuclear factor-κB
por: Jacobs, H, et al.
Publicado: (2011)

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase
por: Feun, L G, et al.
Publicado: (2012)

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer
por: Appels, N M G M, et al.
Publicado: (2008)

Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells
por: Pero, S C, et al.
Publicado: (2007)

Intracellular chemiluminescence activates targeted photodynamic destruction of leukaemic cells
por: Laptev, R, et al.
Publicado: (2006)

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
por: Meng, F, et al.
Publicado: (2013)

Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
por: Vinjamuri, S, et al.
Publicado: (2013)

Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer
por: Duivenvoorden, W C M, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_5j3hrj2900l3rg1cklqpqod2m4